Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Updated Clinical Results: A Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab Plus Chemotherapy

Armin Ghobadi, Robert Baiocchi, Amer M. Beitinjaneh, Sridhar Chaganti, Sylvain Choquet, Daan Dierickx, Rajani Dinavahi, Xinyuan Duan, Laurence Gamelin, Kris Michael Mahadeo, Aditi Mehta, Sarah Nikiforow, Ran Reshef, Sandrine Roye, Jean-Claude Vedovato, Susan E Prockop

Blood (2024) 144 (Supplement 1): 70.

https://doi.org/10.1182/blood-2024-198159

Published: 2024

Journal Articles

Exploring the Impact of Humoral Immunogenicity with Tabelecleucel for the Treatment of EBV + PTLD Following HCT and SOT

Tassja J Spindler, Fiona Ruiz, Tiffany Jehng, Hanna Ding, Norma Guzman-Becerra, Shahram Khanzadeh, Xiaoming Li, Laurence Gamelin, Jason A. Dubovsky, Cokey Nguyen

Blood (2022) 140 (Supplement 1): 7529–7530.

https://doi.org/10.1182/blood-2022-157673

Published: 2022

Journal Articles

Updated Efficacy and Safety of Tabelecleucel in Patients with Epstein-Barr Virus-Positive (EBV + ) Leiomyosarcomas (LMS)

Lauren S Jiménez-Kurlander, Gerald Behr, Nancy J Bunin, Ekaterina Doubrovina, Rajani Dinavahi, Laurence Gamelin, Armin Ghobadi, Leo Mascarenhas, Sarah Nikiforow, Richard J O'Reilly, Anita Price, Barry Shulkin, Ashok Srinivasan, Stephanie Suser, Justin Wahlstrom, Baodong Xing, Susan Prockop

Blood (2022) 140 (Supplement 1): 7524–7526.

https://doi.org/10.1182/blood-2022-157765

Published: 2022

Journal Articles

New and Updated Results from a Multicenter, Open-Label, Global Phase 3 Study of Tabelecleucel (Tab-cel) for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV + PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

Kris Michael Mahadeo, Robert A. Baiocchi, Amer Beitinjaneh, Sridhar Chaganti, Sylvain Choquet, Daan Dierickx, Rajani Dinavahi, Laurence Gamelin, Armin Ghobadi, Norma Guzman-Becerra, Manher Joshi, Aditi Mehta, Sarah Nikiforow, Ran Reshef, Wei Ye, Susan Prockop

Blood (2022) 140 (Supplement 1): 10374–10376.

https://doi.org/10.1182/blood-2022-157766

Published: 2022

Journal Articles

Overall Survival By Best Overall Response with Tabelecleucel in Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Solid Organ or Allogeneic Hematopoietic Cell Transplant

Susan Prockop, Laurence Gamelin, Rajani Dinavahi, Yan Sun, Weizhi Zhao, Faith Galderisi, Aditi Mehta

Blood (2021) 138 (Supplement 1): 887.

https://doi.org/10.1182/blood-2021-147226

Published: 2021

Journal Articles

Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

Susan Prockop, Kris Michael Mahadeo, Amer Beitinjaneh, Sylvain Choquet, Patrick Stiff, Ran Reshef, Gowri Satyanarayana, Saurabh Dahiya, Hema Parmar, Wei Ye, Laurence Gamelin, Rajani Dinavahi

Blood (2021) 138 (Supplement 1): 301.

https://doi.org/10.1182/blood-2021-147274

Published: 2021

Journal Articles

A Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease (EBV + PTLD) after Failure of Rituximab or Rituximab and Chemotherapy

Susan Prockop, MD, Minoti Hiremath, MBBS, PhD, Wei Ye, PhD, Laurence Gamelin, MD, Willis Navarro, MD, Kris Michael Mahadeo, MD

Blood (2019) 134 (Supplement_1): 5326.

https://doi.org/10.1182/blood-2019-129277

Published: 2019

Journal Articles

A Systematic Literature Review and Meta-Analysis of the Risk of Thromboembolic Events in Patients with Immune Thrombocytopenia (ITP) in Observational Studies.

Wendy Langeberg, PhD, MPH, Melissa Eisen, MD, W. Marieke Schoonen, PhD, MPH, Laurence Gamelin, MD, PhD, Scott Stryker, MD, DrPH

Blood (2012) 120 (21): 2187.

https://doi.org/10.1182/blood.V120.21.2187.2187

Published: 2012

NARROW

Updated Clinical Results: A Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab Plus Chemotherapy

Exploring the Impact of Humoral Immunogenicity with Tabelecleucel for the Treatment of EBV + PTLD Following HCT and SOT

Updated Efficacy and Safety of Tabelecleucel in Patients with Epstein-Barr Virus-Positive (EBV + ) Leiomyosarcomas (LMS)

Overall Survival By Best Overall Response with Tabelecleucel in Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Solid Organ or Allogeneic Hematopoietic Cell Transplant

Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

A Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease (EBV + PTLD) after Failure of Rituximab or Rituximab and Chemotherapy

A Systematic Literature Review and Meta-Analysis of the Risk of Thromboembolic Events in Patients with Immune Thrombocytopenia (ITP) in Observational Studies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only